CD24 therefore emerged as an effective target in BCP-ALL, and the combination of CD24 and CD123 as a potential effective double-targeting strategy. The combination of different recognition modalities (eg, a CAR and CD16) should be tested to determine whether it provides synergistic cytotoxic activity in triple targeting.

1 day ago

Journal

CD123 (Interleukin 3 Receptor Subunit Alpha) • CD24 (CD24 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ADAM10 (ADAM Metallopeptidase Domain 10) • ADAM8 (ADAM Metallopeptidase Domain 8)

Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia. (PubMed, Blood)

Patients ≥60 years with Ph-negative B-cell ALL and TP53 VAF ≥45% had poor outcomes, with 4-year event-free survival (EFS) and overall survival (OS) of 28%, driven primarily by increased relapse risk, even among patients treated with frontline inotuzumab ozogamicin (INO) and/or blinatumomab. TP53 persistence at remission occurred in 44% of tested patients and was associated with increased ALL relapse risk. These results demonstrate that TP53 VAF is prognostic in older patients with Ph-negative B-cell ALL; high VAF may increase relapse risk but is not independently associated with survival in younger patients.

2 days ago

Journal

TP53 (Tumor protein P53)

TP53 mutation • TP53 wild-type

Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)

AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P2, N=80, Recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026

3 days ago

Trial completion date • Trial primary completion date

CD22 (CD22 Molecule)

cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate)

10d

NCI-2018-02016: ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P1/2, N=37, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; <75% participation

10 days ago

Trial termination

CD22 (CD22 Molecule)

epratuzumab-cys-tesirine (ADCT-602)

13d

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL (clinicaltrials.gov)

P2, N=42, Recruiting, Sheng-Li Xue, MD | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026

13 days ago

Trial completion date • Trial primary completion date • Minimal residual disease

ABL1 (ABL proto-oncogene 1) • CD22 (CD22 Molecule)

Besponsa (inotuzumab ozogamicin)

14d

A Multi-center Retrospective Study of INO Treating B-ALL (clinicaltrials.gov)

P=N/A, N=102, Active, not recruiting, Ruijin Hospital

14 days ago

New trial

Besponsa (inotuzumab ozogamicin)

15d

The emerging role of immunotherapy in improving outcomes in Down syndrome - associated acute lymphoblastic leukemia: an insightful review. (PubMed, Leuk Lymphoma)

Recent advances in immunotherapy, including blinatumomab, inotuzumab ozogamicin, and CD19-directed CAR T-cell therapy, have shown significant efficacy and favorable tolerability in pediatric and adult DS-ALL. Emerging approaches incorporating early immunotherapy, MRD-guided treatment, and chemotherapy-free regimens may improve survival and quality of life. Prospective DS-specific trials are essential to optimize therapy and close the outcome gap in this high-risk population.

15 days ago

Review • Journal • IO biomarker

ABL1 (ABL proto-oncogene 1) • CRLF2 (Cytokine Receptor Like Factor 2)

Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)

15d

Efficacy and safety of inotuzumab ozogamicin and its combination therapies in acute lymphoblastic leukemia: a systematic review and meta-analysis. (PubMed, Front Oncol)

Further randomized studies are needed to validate these findings. https://www.crd.york.ac.uk/prospero/, identifier CRD42024619042.

15 days ago

Retrospective data • Review • Journal

CD22 (CD22 Molecule)

Besponsa (inotuzumab ozogamicin)

17d

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy (clinicaltrials.gov)

P2, N=55, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | N=31 --> 55

17 days ago

Enrollment change • Minimal residual disease

Besponsa (inotuzumab ozogamicin)

NCI-2018-02016: ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P1/2, N=37, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=57 --> 37

1 month ago

Enrollment closed • Enrollment change

CD22 (CD22 Molecule)

epratuzumab-cys-tesirine (ADCT-602)

Lumi-NHL: A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)

P1/2, N=91, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

1 month ago

Enrollment open